{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-C517SQHW/11a2e5ab-2749-4ad8-99e5-61c3d83b51b9/PDF","dcterms:extent":"236 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-C517SQHW/bcd83cd7-d17f-4a8d-8a73-4e68f0829bae/TEXT","dcterms:extent":"26 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-C517SQHW","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2025","dc:creator":["Mravljak, Janez","Pavlin, Tajda"],"dc:format":[{"@xml:lang":"sl","#text":"številka:5"},{"@xml:lang":"sl","#text":"letnik:76"},{"@xml:lang":"sl","#text":"str. 320-326"}],"dc:identifier":["ISSN:2536-4316","COBISSID_HOST:266065411","URN:URN:NBN:SI:doc-C517SQHW"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"citokrom c oksidaza"},{"@xml:lang":"en","#text":"cytochrome c oxidase"},{"@xml:lang":"en","#text":"hydrogen sulfide"},{"@xml:lang":"en","#text":"neurodegenerative diseases"},{"@xml:lang":"sl","#text":"Nevrodegenerativne bolezni"},{"@xml:lang":"en","#text":"vasodilation"},{"@xml:lang":"sl","#text":"vazodilatacija"},{"@xml:lang":"sl","#text":"vodikov sulfid"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Vodikov sulfid - signalna molekula s terapevtskim potencialom| Hydrogen sulfide - a signaling molecule with therapeutic potential|"},"dc:description":[{"@xml:lang":"sl","#text":"Hydrogen sulfide, along with carbon monoxide and nitric oxide, is an important signaling molecule that is endogenously synthesized by specific enzymes. It is involved in various physiological processes, including vasodilation, neuromodulation, and neuroprotection. Its role in protecting cells from oxidative stress is significant, and research has shown that it also regulates apoptosis and cell proliferation. Additionally, hydrogen sulfide has anti-inflammatory properties, although in some contexts, it may exert pro-inflammatory effects. Despite its many beneficial actions, it is toxic at high concentrations, as it inhibits cytochrome c oxidase, disrupting the respiratory chain, promoting the formation of reactive oxygen species, and leads to cellular damage. hydrogen sulfide donors show potential for treating conditions such as myocardial ischemia, neurodegenerative diseases, and inflammatory disorders; however, their mechanisms of action and safety profiles require further investigation"},{"@xml:lang":"sl","#text":"Vodikov sulfid je poleg ogljikovega monoksida in dušikovega oksida pomembna signalna molekula, ki se endogeno sintetizira s pomočjo specifičnih encimov. Sodeluje pri številnih fizioloških procesih, kot so vazodilatacija, nevromodulacija in zaščita nevronov. Pomembna je tudi njegova vloga pri zaščiti celic pred oksidativnim stresom, raziskave pa so pokazale, da sodeluje pri uravnavanju apoptoze in proliferacije celic. Poleg tega ima proti vnetne učinke, v določenih okoliščinah pa lahko deluje tudi provnetno. Kljub številnim koristnim učinkom je v visokih koncentracijah toksičen, saj zavira citokrom c oksidazo, kar zaustavi delovanje dihalne verige, vodi v nastanek reaktivnih kisikovih zvrsti in poškodbe celic. Donorje vodikovega sulfida bi lahko uporabili za zdravljenje določenih stanj, kot so ishemija miokarda, nevrodegenerativne bolezni in vnetna obolenja, vendar so nujne nadaljnje raziskave glede mehanizmov delovanja in varnosti teh spojin"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-C517SQHW","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-C517SQHW"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-C517SQHW/11a2e5ab-2749-4ad8-99e5-61c3d83b51b9/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-C517SQHW/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-C517SQHW"}}}}